An independent company is to be established and led by BioNTech co-founders Professor Ugur Sahin and Professor Özlem Türeci to “advance next-generation mRNA innovations”.  

BioNTech has announced plans to contribute related rights and mRNA technologies to the new company to support the prioritised development of mRNA innovations with “disruptive potential”. 

BioNTech plans to focus on its growing late-stage pipeline of immunomodulator, antibody-drug conjugate (ADC) and mRNA candidates. It expects to have 15 ongoing Phase III clinical trials in oncology by year end. 

Ugur Sahin and Özlem Türeci will transition into the management of their new company by the end of 2026 after their current service agreements end.

“Over the past 18 years, we have built BioNTech from a start-up into a global biopharmaceutical company with a strong and diversified pipeline. During the Covid-19 pandemic, we expanded beyond oncology to develop the first approved mRNA vaccine, helping to protect people worldwide. Today, the company is well positioned to advance its mission and evolve into a commercial multi-product company. For us, this is the right time to prepare to hand over the baton,” said Professor Sahin. “At the same time, Özlem and I are ready to become pioneers once again. Our vision has always been to translate our science into meaningful advances for patients, and we see extraordinary opportunities to unlock the next generation of transformative innovations.” 

“Over the course of their careers, Ugur and Özlem have established an outstanding track record of innovation,” added Helmut Jeggle, Chairman of the BioNTech Supervisory Board. “We believe that this plan will be additive for both, BioNTech and the new company, as it aims to allow each organisation to drive meaningful impact for patients. We look forward to working together with their new company on potential combination therapy approaches, setting the stage for continued success.”